Steroid-Induced Ocular Hypertension in Mice Is Differentially Reduced by Selective EP2, EP3, EP4, and IP Prostanoid Receptor Agonists

Simple item page
dc.creatorSharif, Najam A.
dc.creatorMillar, J. Cameron
dc.creatorZode, Gulab S.
dc.creatorOta, Takashi
dc.date.accessioned2024-04-05T14:38:24Z
dc.date.available2024-04-05T14:38:24Z
dc.date.issued2024-03-28
dc.description.abstractWe tested five chemically and metabolically stable prostaglandin (PG) receptor agonists in a mouse model of dexamethasone-induced ocular hypertension (OHT). Whilst all compounds significantly (p < 0.05, ANOVA) lowered intraocular pressure (IOP) after twice-daily bilateral topical ocular dosing (5 microg/dose) over three weeks, the time course and magnitude of the responses varied. The onset of action of NS-304 (IP-PG receptor agonist) and rivenprost (EP4-PG receptor agonist) was slower than that of misoprostol (mixed EP2/EP3/EP4-PG receptor agonist), PF-04217329 (EP2-PG receptor agonist), and butaprost (EP2-PG receptor agonist). The rank order of IOP-lowering efficacies aligned with the onset of actions of these compounds. Peak IOP reductions relative to vehicle controls were as follows: misoprostol (74.52%) = PF-04217329 (74.32%) > butaprost (65.2%) > rivenprost (58.4%) > NS-304 (55.3%). A literature survey indicated that few previously evaluated compounds (e.g., latanoprost, timolol, pilocarpine, brimonidine, dorzolamide, cromakalim analog (CKLP1), losartan, tissue plasminogen activator, trans-resveratrol, sodium 4-phenyl acetic acid, etc.) in various animal models of steroid-induced OHT were able to match the effectiveness of misoprostol, PF-04217329 or butaprost. Since a common feature of the latter compounds is their relatively high affinity and potency at the EP2-PG receptor sub-type, which activates the production of intracellular cAMP in target cells, our studies suggest that drugs selective for the EP2-PG receptor may be suited to treat corticosteroid-induced OHT.
dc.description.sponsorshipThis research was funded by the National Eye Institute, EY026177, and Santen Inc.
dc.identifier.citationSharif, N. A., Millar, J. C., Zode, G., & Ota, T. (2024). Steroid-Induced Ocular Hypertension in Mice Is Differentially Reduced by Selective EP2, EP3, EP4, and IP Prostanoid Receptor Agonists. International journal of molecular sciences, 25(6), 3328. https://doi.org/10.3390/ijms25063328
dc.identifier.issn1422-0067
dc.identifier.issue6
dc.identifier.urihttps://hdl.handle.net/20.500.12503/32534
dc.identifier.volume25
dc.publisherMDPI
dc.relation.urihttps://doi.org/10.3390/ijms25063328
dc.rights.holder© 2024 by the authors.
dc.rights.licenseAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceInternational Journal of Molecular Sciences
dc.subjectButaprost
dc.subjectEP2 receptor agonist
dc.subjectIop
dc.subjectPf-04217329
dc.subjectocular hypertension
dc.subjectsteroid
dc.subject.meshMisoprostol / pharmacology
dc.subject.meshMisoprostol / therapeutic use
dc.subject.meshOcular Hypertension / chemically induced
dc.subject.meshOcular Hypertension / drug therapy
dc.subject.meshAcetamides
dc.subject.meshAcetates
dc.subject.meshPyrazines
dc.subject.meshSulfonamides
dc.titleSteroid-Induced Ocular Hypertension in Mice Is Differentially Reduced by Selective EP2, EP3, EP4, and IP Prostanoid Receptor Agonists
dc.typeArticle
dc.type.materialtext

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
10.3390_ijms25063328.pdf
Size:
1.97 MB
Format:
Adobe Portable Document Format
Description:
full text article
Download

Collections

Publications -- Cameron Millar